Sejun Kim

Nov 26, 2024 | onlinelibrary.wiley.com | Sejun Kim |Andreas Jensen |Alexander Egeberg

The long-term safety of ustekinumab was good in terms of malignancy, MACE, or severe infections, and no serious hypersensitivity reactions were observed. Ustekinumab patients were characterized by younger age and a higher proportion of males. Ustekinumab was safe regardless of psoriatic arthritis (PsA) status. 1 Introduction Psoriasis (PsO) is a chronic and recurrent inflammatory skin condition that affects approximately 7.9% of the Danish population [1-3].